Maintain Flexibility in your Workflow without Compromising Quality – Cryopreserved Leukopaks
Alameda, CA – September 15, 2020. AllCells, the leading provider of primary cells supporting biomedical research and commercialization of pharmacological and cellular therapies, announced today the addition of Cryopreserved Leukopaks to their extensive product portfolio. Get the quality of fresh cells with the convenience of cryopreserved cells with this new product offering.
- High-Quality Primary Cells: Superior total nucleated cell count (TNC) and cell viability due to on-site processing facilities, which mitigate loss of fidelity prior to cryopreservation.
- State-of-the-Art Cryopreservation: Cells are cryopreserved using GE Healthcare’s GMP VIA Freeze Quad controlled-rate freezer, which enables consistently high post-thaw recovery and viability.
- Dependable Cold Chain Logistics: AllCells utilizes CryoPort LN2 Dry Shippers for dependable end-to-end shipping logistics.
- Flexibility: Cryopreserved cells give you the flexibility to do experiments on your schedule without waiting on delivery of fresh cells.
“The launch of AllCells cryopreserved leukopaks provides us with a strong position in large and growing market, and will further expand our position in the research market, while providing our expansive customer base logistical flexibility, state of the art cryopreservation methods, coupled with the quality and stability they have come to expect from AllCells,” said Dr. Jay Tong, Founder and CEO.
Leukopaks, collected from peripheral blood from a single donor, are an enriched source of mononuclear cells (MNC, T cells, B cells, NK cells, and monocytes). Leukapheresis collections provide higher purity and quantity of mononuclear cells (MNCs) than buffy coat collection, which is desirable for research and clinical uses such as cell-based assays (proliferation, T cell activation, etc), cell therapy process development, biomarker discovery and more.
With AllCells’ new Cryopreserved Leukopaks, customers have access to high-quality primary cells whenever they need them without worrying about potential delivery delays that can be associated with fresh cells.
AllCells’ Cryopreserved Leukopaks offer a key advantage with acquisition and manufacturing facilities adjacent to each other. This enables the leukapheresis material to be immediately cryopreserved to mitigate cell viability losses between collection and processing events. Additionally, AllCells utilizes a protocol optimized with GE Healthcare’s GMP VIA Freeze Quad controlled-rate freezers, which is based on state-of-the-art conduction cooling. This unique method is gentle on cells, preserving cell function and viability during cryopreservation. To ensure end-to-end cold chain logistics are worry-free, AllCells ships Cryopreserved Leukopaks using CryoPort’s LN2 dry shippers. These shippers maintain temperatures of < -150°C for up to 10 days eliminating temperature excursions and risk of product degradation.
With immediate cell processing and state-of-the-art cryopreservation protocols, AllCells has removed complex logistical and technical challenges in order to safeguard product quality, providing dependable, cold chain logistics to minimize risks during shipping. You can get Cryopreserved Leukopaks with high viability and functionality to achieve flexibility in your workflow without sacrificing quality.
MNC-rich peripheral blood is collected using continuous flow Spectra Optia® Apheresis System into ACD-A anticoagulant following a standardized protocol at our on-site, IRB-approved bi-coastal collection facilities located in Alameda, California and Quincy, Massachusetts from an extensive pool of healthy, consenting, and recallable donors. As with our other products, Cryopreserved Leukopaks upholds AllCells’ strict quality standards to ensure unparalleled purity, viability, and quality.